A CRUK phase I/IIA, first in human dose-escalation and expansion trial of HMBD-001 (an anti-HER-3 antibody) in patients with advanced HER3-positive solid tumours

被引：0

作者：

de Bono, J. S. ^{[1
]}

Lord, S. ^{[2
]}

Yap, C. ^{[3
]}

Rowinsky, E. K. ^{[4
]}

Gandhi, N. A. ^{[4
]}

Thakkar, D. ^{[5
]}

Ingram, P. J. ^{[5
]}

Padmanabhan, N. ^{[6
]}

Chandran, K. ^{[7
,8
]}

Paschalis, A. ^{[9
]}

McGuigan, L. ^{[10
]}

Neal, P. ^{[10
]}

Paisley, D. ^{[10
]}

Walter, H. S. ^{[10
]}

Kelly, F. ^{[10
]}

Craigan, J. ^{[10
]}

Westwood, N. B. ^{[10
]}

Halbert, G. ^{[10
]}

Boyd-Kirkup, J. D. ^{[11
]}

Halford, S. E. R. ^{[10
]}

机构：

[1] ICR Inst Canc Res, London, England

[2] Univ Oxford, Oncol, Oxford, England

[3] ICR Inst Canc Res North Site, Clin Trials Biostat Dept, Sutton, England

[4] Hummingbird Biosci, Dis Area Strategy, Houston, TX USA

[5] Hummingbird Biosci Pte Ltd, Pharmacol Dept, Temasek Lifesci Labs, Singapore, Singapore

[6] Hummingbird Biosci Pte Ltd, Pharmacol, Temasek Lifesci Labs, Singapore, Singapore

[7] Inst Canc Res, Med Oncol, Sutton, England

[8] Royal Marsden Hosp, Sutton, England

[9] ICR Inst Canc Res, Clin Studies, London, England

[10] CRUK Canc Res UK, Ctr Drug Dev, London, England

[11] Hummingbird Biosci Pte Ltd, Res, Temasek Lifesci Labs, Singapore, Singapore

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期

关键词：

D O I：

10.1016/j.annonc.2022.07.621

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

493TiP

引用

页码：S767 / S767

页数：1

共 50 条

[41] HLX22, an anti-HER-2 monoclonal antibody, in patients with advanced solid tumors overexpressing human epidermal growth factor receptor 2: an open-label, dose-escalation, phase 1 trial
Zhu, Xiaoxue
Ding, Yanhua
Wang, Qian
Yang, Guiyu
Zhou, Liang
Wang, Qingyu
INVESTIGATIONAL NEW DRUGS, 2023, 41 (03) : 473 - 482
[42] MITOPE trial-in-progress: first-in-human dose-escalation and expansion study to evaluate mitochondrial PRX3 inhibition by RSO-021 in patients with mesothelioma and other advanced solid tumours
Naumov, George
Fennell, Dean
LUNG CANCER, 2023, 178 : S90 - S90
[43] A phase 1 dose-escalation study of anti-HER3 monoclonal antibody LJM716 in combination with trastuzumab in patients with HER2-overexpressing metastatic breast or gastric cancer
Im, Seock-Ah
Juric, Dejan
Baselga, Jose
Kong, Anthony
Martin, Paloma
Lin, Chia-Chi
Dees, Elizabeth Claire
Schellens, Jan H. M.
De Braud, Filippo G.
Delgado, Lily
Zucchetto, Mauro
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Dirix, Luc Yves
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[44] A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Kerry Lynn Reynolds
Philippe L. Bedard
Se-Hoon Lee
Chia-Chi Lin
Josep Tabernero
Maria Alsina
Ezra Cohen
José Baselga
George Blumenschein
Donna M. Graham
Ignacio Garrido-Laguna
Dejan Juric
Sunil Sharma
Ravi Salgia
Abdelkader Seroutou
Xianbin Tian
Rose Fernandez
Alex Morozov
Qing Sheng
Thiruvamoor Ramkumar
Angela Zubel
Yung-Jue Bang
BMC Cancer, 17
[45] Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2-and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial
Costa, Ricardo L.
Childress, Jennifer A.
Abraham, Edith
Farrell, Carly
Mo, Qianxing
Jameel, Zena
Muller, Aixa Elena Soyano
Lee, Kimberley T.
Hoover, Susan
Kiluk, John
Weinfurtner, Robert J.
Lee, Marie Catherine
Laronga, Christine
Khakpour, Nazanin
Han, Hyo S.
Khong, Hung T.
Soliman, Hatem Hussein
Czerniecki, Brian J.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[46] A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer
Reynolds, Kerry Lynn
Bedard, Philippe L.
Lee, Se-Hoon
Lin, Chia-Chi
Tabernero, Josep
Alsina, Maria
Cohen, Ezra
Baselga, Jose
Blumenschein, George, Jr.
Graham, Donna M.
Garrido-Laguna, Ignacio
Juric, Dejan
Sharma, Sunil
Salgia, Ravi
Seroutou, Abdelkader
Tian, Xianbin
Fernandez, Rose
Morozov, Alex
Sheng, Qing
Ramkumar, Thiruvamoor
Zubel, Angela
Bang, Yung-Jue
BMC CANCER, 2017, 17
[47] A phase I, dose-escalation study of PF-06650808, an anti-Notch3 antibody–drug conjugate, in patients with breast cancer and other advanced solid tumors
Lee S. Rosen
Robert Wesolowski
Raffaele Baffa
Kai-Hsin Liao
Steven Y. Hua
Brenda L. Gibson
Steven Pirie-Shepherd
Anthony W. Tolcher
Investigational New Drugs, 2020, 38 : 120 - 130
[48] Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in- human, open-label, dose-escalation phase I study with expansion cohort
Burris, Howard A.
Bakewell, Suzanne
Bendell, Johanna C.
Infante, Jeffrey
Jones, Suzanne F.
Spigel, David R.
Weiss, Glen J.
Ramanathan, Ramesh K.
Ogden, Angela
Von Hoff, Daniel
ESMO OPEN, 2016, 1 (06)
[49] A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors
ODonnell, P.
Goldman, J. W.
Gordon, M. S.
Shih, K.
Choi, Y. J.
Lu, D.
Kabbarah, O.
Ho, W.
Rooney, I.
Lam, E. T.
EUROPEAN JOURNAL OF CANCER, 2012, 48 : 191 - 192
[50] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
Bendell, Johanna C.
Patel, Manish R.
Moore, Kathleen N.
Chua, Cynthia C.
Arkenau, Hendrik-Tobias
Dukart, Gary
Harrow, Kim
Liang, Chris
ONCOLOGIST, 2019, 24 (04): : 455 - E121

← 1 2 3 4 5 →